Acorda Therapeutics, Inc. | TalkMarkets | Page 1
No data available
No data available

People who follow this stock (37)

View All

Latest Posts

About This Stock More About This Stock
Week In Review: BlissBio Announces Potential $2 Billion Deal With Eisai For HER2 ADC
Article By: ChinaBio® Today
Saturday, May 13, 2023 3:00 PM EDT
Bliss Biopharma may out-license global rights for its HER2 ADC to Eisai Pharma in a deal with a potential value of $2 billion. Also, Junshi Bio out-licensed regional rights for its anti-PD-1 mAb to Dr. Reddy’s Labs in a deal worth up to $728 million.
In this article: ESAIY Also: RDY, RHHBY, ACOR, LIAN, EQRX, IVBXF, CSPHF
Read
Week In Review: Biocytogen, A Genetically Modified Animal Models Company, Stages $60 Million IPO
Article By: ChinaBio® Today
Saturday, September 3, 2022 3:51 PM EDT
Beijing Biocytogen Pharma completed a $60 million IPO on the Hong Kong Exchange for its genetically modified animal and cell model business, which it offers to pharmaceutical/biotech companies. Biocytogen has a market capitalization of $357 million. 
In this article: 2315.HK Also: JNJ, ACOR, IMAB, 300558.SZ, 2257.HK
Read
Worst Stocks Of The Decade
Article By: Bespoke Investment Group
Wednesday, December 18, 2019 4:00 PM EDT
While there have been a lot of big winners in the stock market in the past decade, there have been a number of big losers as well.
In this article: CHK, FTR, JCPNQ, MDR, NE, RIG, UNT, VAL, WLL, ACOR
Read
The Daily Biotech Pulse: Amgen Takes 20.5% Stake In BeiGene, Paratek's Mixed Clinical Readout, CareDx Slips On Guidance
Article By: Benzinga
Friday, November 1, 2019 7:38 AM EDT
Here's a roundup of top developments in the biotech space over the last 24 hours.
In this article: AMGN, BGNE, MNK, PRTK, IDYA, CDNA, BLUE Also: HOTH, AGN, AZN, BMY, GSK, RMD, ACOR, ACRX, ALIM, AMAG, BCRX, CERS, IMGN, NURO, RMTI, CELG, VRTX, ABBV, AGIO, REPH, RETA, PRTO, MGNX, OPGN, MGEN, DOVA, DRNA, DCPH, TRVI, OYST, RAPT, ARDS, MIRM, ITRM, COCP, CYCN, GMAB
Read
Acorda Falls 37% After Five Deaths Stop Enrollment In Parkinson's Study
Article By: The Fly
Wednesday, November 15, 2017 10:25 AM EDT
Shares of Acorda Therapeutics are sinking after the company announced this morning that it has increased the frequency of blood cell count monitoring for participants to weekly in its Phase 3 program of tozadenant for Parkinson's disease.
In this article: ACOR
Read
All Posts

Latest Tweets for $ACOR

No tweets yet!

PARTNER HEADLINES